Association Between Perioperative Fibrinogen Levels and the Midterm Outcome in Patients Undergoing Elective Endovascular Repair of Abdominal Aortic Aneurysms

Kapetanios, Dimitrios; Karkos, Christos D.; Pliatsios, Ioannis; Mitka, Maria; Giagtzidis, Ioakeim T.; Konstantinidis, Konstantinos; Papazoglou, Konstantinos

doi:10.1016/j.avsg.2018.09.021

Cited by 9 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platelets, in conjugation with endothelial cells and coagulation proteins, are the crucial mediator of vascular hemostasis and thrombosis. Disruption to any of these processes could result in atherosclerotic plaque formation [9][10][11] (Figure 2, leading to variety of thrombotic diseases including CVDs (cardiovascular diseases) [12,13], abdominal aortic aneurysms (AAAs) [14,15], pulmonary embolism (PE) [16], and stroke [17,18]. The process of hemostasis is divided into two stages: (1) primary (involves rapid platelet activation) and (2) secondary (requires additional coagulation pathways to form polymeric fibrin) processes (Table 1).…”

Section: Mechanism Of Thrombus Formationmentioning

confidence: 99%

“…Platelets, in conjugation with endothelial cells and coagulation proteins, are the crucial mediator of vascular hemostasis and thrombosis. Disruption to any of these processes could result in atherosclerotic plaque formation [ 9 , 10 , 11 ] ( Figure 2 , leading to variety of thrombotic diseases including CVDs (cardiovascular diseases) [ 12 , 13 ], abdominal aortic aneurysms (AAAs) [ 14 , 15 ], pulmonary embolism (PE) [ 16 ], and stroke [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Thrombolytic Enzymes of Microbial Origin: A Review

Diwan

Usmani

Sharma

et al. 2021

IJMS

View full text Add to dashboard Cite

Enzyme therapies are attracting significant attention as thrombolytic drugs during the current scenario owing to their great affinity, specificity, catalytic activity, and stability. Among various sources, the application of microbial-derived thrombolytic and fibrinolytic enzymes to prevent and treat vascular occlusion is promising due to their advantageous cost–benefit ratio and large-scale production. Thrombotic complications such as stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, and peripheral occlusive diseases resulting from blood vessel blockage are the major cause of poor prognosis and mortality. Given the ability of microbial thrombolytic enzymes to dissolve blood clots and prevent any adverse effects, their use as a potential thrombolytic therapy has attracted great interest. A better understanding of the hemostasis and fibrinolytic system may aid in improving the efficacy and safety of this treatment approach over classical thrombolytic agents. Here, we concisely discuss the physiological mechanism of thrombus formation, thrombo-, and fibrinolysis, thrombolytic and fibrinolytic agents isolated from bacteria, fungi, and algae along with their mode of action and the potential application of microbial enzymes in thrombosis therapy.

show abstract

Section: Mechanism Of Thrombus Formationmentioning

confidence: 99%

“…Platelets, in conjugation with endothelial cells and coagulation proteins, are the crucial mediator of vascular hemostasis and thrombosis. Disruption to any of these processes could result in atherosclerotic plaque formation [ 9 , 10 , 11 ] ( Figure 2 , leading to variety of thrombotic diseases including CVDs (cardiovascular diseases) [ 12 , 13 ], abdominal aortic aneurysms (AAAs) [ 14 , 15 ], pulmonary embolism (PE) [ 16 ], and stroke [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Thrombolytic Enzymes of Microbial Origin: A Review

Diwan

Usmani

Sharma

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Initiation of the blood clotting process occurs at the wound site when platelets are aggregated and a proteolytic cascade mechanism to convert fibrinogen into fibrin is started (Doolittle, 2010;Weisel and Litvinov, 2017). Normally these clots are hydrolyzed by plasmin; however, aberrant control of the hydrolysis process could cause hyperfibrinogenemia, which, subsequently, leads to a variety of thrombotic diseases such as stroke (Danesh et al, 2005;Chelluboina and Vemuganti, 2019), abdominal aortic aneurysm (Parry et al, 2009;Kapetanios et al, 2019), peripheral vascular disease (Altes et al, 2018), pulmonary embolism (Klovaite et al, 2013), and cardiovascular disease (CVD) (Tatli et al, 2009;Liu et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Role of Fibrinolytic Enzymes in Anti-Thrombosis Therapy

Altaf

Kasim

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Thrombosis, a major cause of deaths in this modern era responsible for 31% of all global deaths reported by WHO in 2017, is due to the aggregation of fibrin in blood vessels which leads to myocardial infarction or other cardiovascular diseases (CVDs). Classical agents such as anti-platelet, anti-coagulant drugs or other enzymes used for thrombosis treatment at present could leads to unwanted side effects including bleeding complication, hemorrhage and allergy. Furthermore, their high cost is a burden for patients, especially for those from low and middle-income countries. Hence, there is an urgent need to develop novel and low-cost drugs for thrombosis treatment. Fibrinolytic enzymes, including plasmin like proteins such as proteases, nattokinase, and lumbrokinase, as well as plasminogen activators such as urokinase plasminogen activator, and tissue-type plasminogen activator, could eliminate thrombi with high efficacy rate and do not have significant drawbacks by directly degrading the fibrin. Furthermore, they could be produced with high-yield and in a cost-effective manner from microorganisms as well as other sources. Hence, they have been considered as potential compounds for thrombosis therapy. Herein, we will discuss about natural mechanism of fibrinolysis and thrombus formation, the production of fibrinolytic enzymes from different sources and their application as drugs for thrombosis therapy.

show abstract